Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation
Information source: Medical University of South Carolina
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cataract Extraction
Intervention: Acular LS (Drug); Lotemax (Drug)
Phase: Phase 4
Sponsored by: Medical University of South Carolina
Official(s) and/or principal investigator(s):
Kerry D Solomon, MD, Principal Investigator, Affiliation: Medical University of South Carolina
The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the
prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan,
Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and
Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch &
Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery.
Official title: Comparison of Acular LS With Lotemax to Prevent Anterior Segment Inflammation After Phacoemulsification and Intraocular Lens Implantation
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAIDs) which, when
administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic
activity. The mechanism of its action is thought to be due to its ability to inhibit
prostaglandin biosynthesis (cyclo-oxigenase inhibitors). However, they leave the
lipoxygenase pathway free to generate leukotrienes. This pharmacodynamic activity has been
speculated as a reason why NSAIDs produce less ocular side effects than corticosteroids. It
has been widely used in ophthalmology. In 1987, Flach1 published its effectiveness in the
treatment of aphakic and pseudophakic macular edema. Its efficacy after cataract surgery has
been shown2 and it has been compared to topical steroids after extra-capsular cataract
extraction3,4,5 and phacoemulsification6,7. It has been used as analgesic after radial
keratotomy(RK)8,9, photorefractive keratectomy (PRK)10 and laser in situ keratomileusis
The purpose of this study is to compare the effectiveness of the NSAID ketorolac tromethamine
ophthalmic solution 0. 4% with the steroid loteprednol etabonate ophthalmic suspension 0. 5%
for preventing anterior segment inflammation after routine cataract surgery.
Minimum age: 18 Years.
Maximum age: N/A.
- Subject must have a visually significant age-related cataract, in the planned operated
- 18 years of age or older.
- The vision in the fellow, unoperated eye should have a potential visual acuity of
20/40 or better as determined by the principal investigator.
- Patient must desire cataract extraction.
- Willing and able to comply with scheduled visits and other study procedures.
- Advanced glaucomatous damage.
- Any abnormality preventing reliable applanation tonometry in operated eye.
- Contact lens use during the active treatment portion of the trial in the operated
- Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis in
- Any history of allergic hypersensitivity or poor tolerance to any component of the
preparations used in this trial.
- Pregnant or nursing mothers and females of childbearing potential not practicing a
reliable and medically acceptable method of birth control.
- Any clinically significant, serious or severe medical or psychiatric condition.
- Participation in (or current participation) any investigational drug or device trial
within the previous 30 days prior to the start date of this trial.
- Intraocular conventional surgery within the past three months or intraocular laser
surgery within one month in the operated eye.
- Required use of other topical medications during the active portion of the trial
except prophylactic antibiotic, topical lid care, tear replacement solutions or
- Other ocular surgery at the time of the cataract extraction.
- Use of topical or oral antiprostaglandins or corticosteroids as well as aspirin
products (> 81 mg) during the active treatment portion of the trial. If patient wants
to participate in the trial and can stop the medication, he/she can be enrolled after
7-day wash out period.
Locations and Contacts
Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina 29425, United States
Starting date: February 2006
Ending date: September 2007
Last updated: October 1, 2007